Erythema gyratum repens

WikiDoc Resources for Erythema gyratum repens
Articles
Most recent articles on Erythema gyratum repens Most cited articles on Erythema gyratum repens Review articles on Erythema gyratum repens Articles on Erythema gyratum repens in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Erythema gyratum repens Images of Erythema gyratum repens Photos of Erythema gyratum repens Podcasts & MP3s on Erythema gyratum repens Videos on Erythema gyratum repens
Evidence Based Medicine
Cochrane Collaboration on Erythema gyratum repens Bandolier on Erythema gyratum repens TRIP on Erythema gyratum repens
Clinical Trials
Ongoing Trials on Erythema gyratum repens at Clinical Trials.gov Trial results on Erythema gyratum repens Clinical Trials on Erythema gyratum repens at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Erythema gyratum repens NICE Guidance on Erythema gyratum repens NHS PRODIGY Guidance FDA on Erythema gyratum repens CDC on Erythema gyratum repens
Books
Books on Erythema gyratum repens
News
Erythema gyratum repens in the news Be alerted to news on Erythema gyratum repens News trends on Erythema gyratum repens
Commentary
Blogs on Erythema gyratum repens
Definitions
Definitions of Erythema gyratum repens
Patient Resources / Community
Patient resources on Erythema gyratum repens Discussion groups on Erythema gyratum repens Patient Handouts on Erythema gyratum repens Directions to Hospitals Treating Erythema gyratum repens Risk calculators and risk factors for Erythema gyratum repens
Healthcare Provider Resources
Symptoms of Erythema gyratum repens Causes & Risk Factors for Erythema gyratum repens Diagnostic studies for Erythema gyratum repens Treatment of Erythema gyratum repens
Continuing Medical Education (CME)
CME Programs on Erythema gyratum repens
International
Erythema gyratum repens en Espanol Erythema gyratum repens en Francais
Business
Erythema gyratum repens in the Marketplace Patents on Erythema gyratum repens
Experimental / Informatics
List of terms related to Erythema gyratum repens

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Gammel's disease.

Historical Perspective

• In 1925 Rothman wrote a comprehensive review on the subject of cutaneous manifestations in patients with malignant tumors and since then cases were added to proof for the relationship between internal neoplasm and some skin lesions.
• In 1953, the dermatologist, Dr. John A Gammel who was trained to link bizarre or recalcitrant dermatoses to internal diseases was the first one who described and labeled Erythema Granulatum Repens in a 55-year-old patient who had been complaining of pruritic scaly skin eruption and found few months later to have poorly differentiated adenocarcinoma.
• Up to 1992, there were only 49 cases in the literature, 41 of which (84%) were associated with a neoplasm
• EGR is associated with internal malignancy in 82% of cases. However, between 1990 and 2010, data was collected from the medical records of patients form dermatology department in University of Genoa and from databases as pubmed and medline, the conclusion of this literature review was that EGR is no longer considered as an obligate paraneoplastic syndrome. More than expected cases of EGR were found with no neoplasm association
• Non-paraneoplastic EGR could be:
  • Idiopathic EGR
  • EGR-like eruptions (different dermatologic lesions that mimic EGR)
  • EGR with concomittant skin disease as:
    • pityriasis rubra pilaris, psoriasis, ichthyosis, CREST, rheumatoid arthritis, tuberculosis, bullous pemphigoid, linear IgA disease, and hypereosinophilic syndrome
  • Drug-induced EGR examples are:
    • Azathioprine with type I autoimmune hepatitis
    • Interferon given for hepatitis C virus–related chronic hepatitis

Classification

• There is no established system for the classification of EGR.

Pathophysiology

• The cause of EGR has not been identified.
• Many theories suggest that EGR is due to immunologic mechanisms
• The immunologic mechanism theory is evidenced by the observed immunofluorescence patterns of IgG, C3, and C4 at the basement membrane:
  • Theory 1 the tumor induces antibodies that cross-react with the basement membrane of skin
  • Theory 2 the tumor produces polypeptides that bind skin antigens and render them immunogenic 
  • Theory 3 deposition of tumor antigen-antibody complexes onto the basement membrane causes the reactive dermatitis seen in EGR

Causes

• The cause of erythema gyratum repens has not been identified.
• Different theories suggest that EGR etiology is stemmed from immunologic reaction

Differentiating Erythema Gyratum Repens from Other Diseases

• EGR has a narrow differential diagnosis and it has to be differentiated from skin lesions with gyrate erythematous eruptions, such as:
  • Necrolytic migratory erythema (NME)
  • Erythema annulare centrifugum (EAC)
  • Erythema chronicum migrans
  • Erythema marginatum rheumaticum

	EGR	EAC	ACM	EMR
Reactive erythema (figurate or Gyrate)	Yes	Yes	Yes
Associated malignancy?	more closely associated (84%)	only a minority of patients	Mainly gluconoma
Most common associated neoplasm	lung cancer     esophageal cancer    Breast cancer metastatic cancer with an unknown origion Cervical, stomach, and pharyngeal cancer (less common)	no particular type of cancer appears to predominate    mutinous ovarian carcinoma    bronchial carcinoma    myeloma
Other association	tuberculosis CREST syndrome (calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia).	infections and allergic reactions to drugs
Skin lesion description	migratory annular and configurate erythematous bands that form concentric rings   Wood grain scaly appearance scale follows the leading edge of the bands. cover the trunk and proximal extremities, sparing the hands, feet, and face.    Eruption migrates more rapidly, 1cm/d	migratory annular and configurate annular or polycyclic lesions which may begin as urticaria-like papules Urticarial in appearance ringed, arcuate figures erythematous lesions    cover only a small percentage of the total body surface  migrate at a slower rate (2 -3 mm/d) reaching up to 10 cm in diameter and resulting in central clearing.
First named by	Gammel in 1952	Darier 1916
Incidence	Very rare	uncommon but not rare
Demographics	Caucasian male: female ratio is 2: 1 average age was 62 years.	no tendency for EAC to favor any age, race, or sex.
Subgroups		Deep: Firm border, rarely pruritic, no scales Superficial: indistinct scaly border , usually pruritic,
Histopathology	Nonspecific moderate perivascular lymphohistiocytic infiltrate    mild focal spongiosis parakeratosis    Eosinophils and melanophages have also been reported in the dermal infiltrate	deep form mononuclear, perivascular infiltrate is present in the middle and lower portions of the dermis (coat sleeve-like configuration) infiltrate is usually composed primarily of lymphocytes, but eosinophils are occasionally present Extravasation of erythrocytes is associated with endothelial swelling    no epidermal changes    superficial more non-specific slight superficial perivascular lymphohistiocytic infiltrate    focal parakeratosis and mild spongiosis with microvesiculation
Lab finding	No specific laboratory changes are associated Eosinophilia has been reported Decreased T lymphocytes and increased B lymphocytes were observed in an EGR patient with increased luteinizing hormone and follicle-stimulating hormone as well as decreased serum levels of C3    Normal percentages of B and T lymphocytes and normal T-cell function were reported in an EGR patient without cancer. Therefore, it appears that any laboratory abnormality detected in patients with EAC or EGR would reflect the underlying etiology of the reactive erythema.	No specific laboratory changes are associated Eosinophilia of the peripheral blood, as well as tissue, can be observed in EAC associated with a drug reaction or parasitic infection    Decreased T lymphocytes and increased B lymphocytes
	Extensive evaluation for possible cancer EGR patients with underlying malignancies had cancers associated with tobacco abuse.	Evaluation for possible infection or drug reaction (prescribed and non-prescribed) complete blood count, urinalysis, and routine serum liver and kidney function tests.
Treatment	identification and treatment of the underlying condition, as the course of either eruption usually parallels that of the underlying process.	identification and treatment of the underlying condition, as the course of either eruption usually parallels that of the underlying process.
	Symptomatic therapy as antihistamine and corticosteroids	systemic corticosteroids for the deep form and topical corticosteroids for the superficial form Lesions of EAC, however, frequently recur following discontinuation of such treatment

Epidemiology and Demographics

• EGR is a rare dermatologic disease, usually associated with paraneoplastic neoplasm

Age

• The average age of onset of EGR is in the seventh decade of life

Gender

• The male to female ratio is 2:1

Race

• EGR commonly affects Caucasians

Risk Factors

• There are no established risk factors for EGR

Screening

• There are no screening tests for EGR.
• Screening for internal malignancy should be done immediately after EGR is diagnosed.

Natural History, Complications, and Prognosis

• The majority of patients with EGR presents with severely pruritic erythematous skin lesions that appear several months prior to the malignancy diagnosis
• If the underlying malignancy left untreated, the debilitating pruritus could persist until the patient dies
• Prognosis depends on the type of the underlying tumor and the probability of its treatment.

Diagnosis

Diagnostic Study of Choice

• EGR is mainly diagnosed clinically by its characteristic skin lesions.

History and Symptoms

• The universal symptoms of EGR are:
  • Skin eruptions
  • Intense pruritus
• Other symptoms related to the associated internal malignancy are:
  • Weight loss
  • Anorexia
  • Fatigue
  • Fever

Physical Examination

• Patients with EGR presents with a rash consisting of wavy erythematous concentric bands that can be figurate, gyrate, or annular.
• The bands are arranged in parallel rings and lined by a fine trailing edge of scale, a pattern often described as “wood grained.
• The rash typically involves large areas of the body but tends to spare the face, hands, and feet and it can expand as fast as a cm a day.
• Bullae can also form from within the areas of erythema

Laboratory Findings

• There are no diagnostic laboratory findings associated with EGR.
• Eosinophilia is observed in 60% of cases

Imaging Findings

• There are no imaging findings associated with EGR.
• Imaging of the chest and abdomen could show malignancy findings.

Other Diagnostic Studies

• Direct immunofluorescence in some cases shows patterns of IgG, C3, and C4 at the basement membrane
• The histopathologic features of EGR is non-specific.
• Biopsy specimens show the following:
  • Acanthosis, mild hyperkeratosis, focal parakeratosis, and spongiosis confined to the epidermis and superficial dermis.
  • Mononuclear, lymphocytic, and histiocytic perivascular infiltrate in the superficial plexus can also be seen
• Thorough paraneoplastic workup includes:
  • Computed tomography of thorax, abdomen, and pelvis
  • Positron emission tomography/computed tomography
  • Upper and lower gastrointestinal endoscopy
  • Tumor markers
  • Blood tests including lactate dehydrogenase and QuantiFERON to exclude tuberculosis.

Treatment

Medical Therapy

• There is no treatment for EGR; the mainstay of therapy is supportive care and treating the underlying condition
• Various dermatologic and immunosuppressive therapies have been used to treat EGR.
• Systemic steroids are frequently ineffective.
• Topical steroids, vitamin A, and azathioprine have also failed to relieve skin manifestations.
• Improvement of EGR, and its associated intense pruritus depends on recognition and treatment of the underlying malignancy.
• Chemotherapy can be used to treat the internal malignancy.

Surgery

• Surgical resection of the internal tumor could be recommended as part of the management of EGR.

Prevention

• There are no primary preventive measures available for [disease name].